Why Compare These Two Leading Weight Management Options?
Mounjaro vs Wegovy Weight Loss: Current UK Stock Availability
The weight management landscape has been challenging for UK patients, with supply disruptions affecting access to these innovative treatments. At EverydayMeds, we've secured reliable stock levels for both Mounjaro and Wegovy, ensuring you can start your weight loss journey without delays. Our pharmaceutical supply chain partnerships with Novo Nordisk (Wegovy) and Eli Lilly (Mounjaro) assurance consistent availability across all licensed doses. Both treatments require a prescription-only medicine assessment, but our streamlined process means approved patients can receive their medication within 24 hours of clinical approval.
Understanding the differences between these treatments is crucial for making an informed decision. Mounjaro (tirzepatide) represents a newer class of dual-action medications, targeting both GIP and GLP-1 receptors, whilst Wegovy focuses solely on GLP-1 receptor activation. Both treatments have demonstrated significant efficacy in clinical trials when used alongside a reduced-calorie diet and increased physical activity. Your prescriber will consider factors including your medical history, current medications, and lifestyle preferences when recommending the most suitable option.
Wegovy Pricing and Value for Mounjaro vs Wegovy Weight Loss Decisions
Wegovy pricing starts at £79.99 for the 0.25mg starter dose, with our tiered pricing structure reflecting the clinical dose escalation schedule. The complete journey includes 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), and 2.4mg maintenance (£209.99). New customers can apply discount code FIRST40 at checkout, whilst returning customers benefit from code DOSE25. These prices represent excellent value considering Wegovy's proven clinical track record and the convenience of once-weekly administration.
Our bundle options provide additional convenience for patients committed to their weight management journey. The Intro Duo (0.25mg & 0.5mg) costs £169.99, covering your first eight weeks of treatment. For those progressing through escalation, the Progress Duo (0.5mg & 1mg) at £189.99 ensures seamless transition between doses. The Ultimate Stability Trio (three 2.4mg pens) at £649.99 provides three months of maintenance therapy, eliminating the need for frequent reorders.
Clinical Evidence Behind Mounjaro vs Wegovy Weight Loss Outcomes
The STEP clinical trial programme demonstrated Wegovy's efficacy across diverse patient populations. In STEP 1, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 2 focused on patients with type 2 diabetes, showing 9.6% average weight reduction, whilst STEP 3 combined Wegovy with intensive behavioural therapy for 16% average weight loss.
Mounjaro's clinical evidence comes from the SURMOUNT trials, which evaluated tirzepatide specifically for weight management in non-diabetic adults. These trials demonstrated significant weight reduction potential, though direct comparison with Wegovy results isn't appropriate due to different study designs and patient populations. Both medications require ongoing use for sustained benefits, as demonstrated in long-term extension studies showing weight regain when treatment is discontinued.
How Wegovy Works in Mounjaro vs Wegovy Weight Loss Comparisons
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of naturally occurring incretin hormones in your digestive system. When you eat, GLP-1 is normally released from your intestines, signalling to your brain that you're becoming full and should reduce food intake. Wegovy amplifies this natural satiety signal, helping you feel satisfied with smaller portions and reducing between-meal cravings. The medication also slows gastric emptying, meaning food stays in your stomach longer, contributing to prolonged feelings of fullness. Unlike Mounjaro's dual-receptor approach, Wegovy focuses exclusively on GLP-1 pathways, providing targeted appetite regulation that has been extensively studied in clinical trials. This mechanism requires weekly injection using the convenient FlexTouch pre-filled pen, designed for simple subcutaneous administration.
Ordering Process for Mounjaro vs Wegovy Weight Loss Treatments
Starting your weight management journey with either Mounjaro or Wegovy begins with our 3-minute online clinical assessment, designed to capture essential medical information for prescriber review. Our qualified prescribers evaluate your suitability for these prescription-only medicines, considering factors like BMI, existing health conditions, current medications, and weight management goals. Standard prescriber review takes up to 3 working days, though our express service provides 24-hour assessment for urgent cases. Once approved, your medication is dispatched via temperature-controlled, next-day delivery to ensure product integrity from our GPhC-registered pharmacy directly to your door. The entire process maintains clinical safety standards whilst prioritising convenience and discretion for busy patients.
Storage and Practical Considerations for Mounjaro vs Wegovy Weight Loss Options
Storage requirements differ between these treatments, potentially influencing your choice for practical reasons. Wegovy offers superior travel convenience, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day limit. Both require standard refrigeration at 2-8°C before first use, but Wegovy's extended room temperature stability benefits frequent travelers or those with unpredictable schedules. The FlexTouch pen system used for Wegovy delivers consistent, controlled doses with each injection, whilst the mandatory dose escalation schedule (0.25mg to 2.4mg over 16 weeks) helps minimise gastrointestinal side effects commonly associated with GLP-1 medications.
Supply Chain Reliability for Mounjaro vs Wegovy Weight Loss Availability
Historical supply challenges have frustrated patients seeking consistent access to weight management medications across the UK. EverydayMeds has invested significantly in supply chain partnerships and inventory management to ensure both Mounjaro and Wegovy remain available when patients need them. Our direct relationships with manufacturers Novo Nordisk and Eli Lilly provide advance visibility of production schedules and potential supply constraints. We maintain strategic stock levels across all licensed doses, preventing the treatment interruptions that can compromise weight management progress.
Our inventory management system automatically alerts patients when their next dose is due, helping maintain treatment continuity essential for sustained weight loss outcomes. Unlike some pharmacies operating on just-in-time inventory models, we deliberately overstock to buffer against unexpected demand spikes or supply disruptions. This approach ensures that patients choosing either treatment option can rely on consistent availability throughout their weight management journey.
Making Your Mounjaro vs Wegovy Weight Loss Decision Today
Both treatments are available immediately through EverydayMeds, eliminating availability concerns from your decision-making process. New customers can start with Wegovy using discount code FIRST40, bringing the 0.25mg starter dose to £79.99, whilst returning customers benefit from code DOSE25 for ongoing savings. Our clinical team, operating under GPhC registration #9012878, provides expert guidance to help identify the most appropriate treatment based on your individual circumstances. Whether you choose Mounjaro's dual-action approach or Wegovy's proven GLP-1 pathway, both options are supported by robust clinical evidence and practical delivery solutions. Remember that successful weight management requires combining these prescription-only medicines with lifestyle modifications including reduced-calorie diet and increased physical activity for optimal outcomes. Order your assessment today to begin your personalised weight management journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
